Xeris appoints James Brady to board, directors Ricki Fairley and John Schmid depart

Xeris Biopharma Holdings, Inc.

Ricki Fairley resigned effective March 28, 2025; no disagreement with company.
John Schmid will not stand for reelection at 2025 Annual Meeting; board to reduce to eight members.
James Brady appointed as Class I director, will chair Audit Committee if reelected.
Brady brings 30+ years at AstraZeneca, most recently CFO of MedImmune; also serves on Verona Pharma (VRNA) board.
Brady received initial equity grant of 100,000 RSUs under non-employee director compensation plan.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Ricki Fairley

Director

XERS · Xeris Biopharma Holdings, Inc.

Effective: 2025-03-28
Filed: March 28, 2025, 7:59 PM ET

On March 28, 2025, Ms. Ricki Fairley, a director of Xeris Biopharma Holdings, Inc. (the “Company”), notified the Company of her decision to resign from the Board of Directors (the “Board”) of the Company, effective as of March 28, 2025.

Appointed

James Brady

Director

XERS · Xeris Biopharma Holdings, Inc.

Effective: 2025-03-28
Filed: March 28, 2025, 7:59 PM ET

On March 28, 2025, the Board appointed Mr. James Brady to the Company’s Board, effective on such date.

Departed

John Schmid

Director

XERS · Xeris Biopharma Holdings, Inc.

Filed: March 28, 2025, 7:59 PM ET

On March 28, 2025, Mr. John Schmid informed the Board of his decision to not stand for reelection as a director at the Company’s 2025 annual meeting of stockholders (the “2025 Annual Meeting”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ricki Fairley resigned as Director at Xeris Biopharma Holdings, Inc..

Action: resigned
Role: Director

Exact text from the filing

On March 28, 2025, Ms. Ricki Fairley, a director of Xeris Biopharma Holdings, Inc. (the “Company”), notified the Company of her decision to resign from the Board of Directors (the “Board”) of the Company, effective as of March 28, 2025.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

James Brady was appointed as Director at Xeris Biopharma Holdings, Inc..

Action: appointed
Role: Director

Exact text from the filing

On March 28, 2025, the Board appointed Mr. James Brady to the Company’s Board, effective on such date.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

John Schmid departed as Director at Xeris Biopharma Holdings, Inc..

Action: not stand for reelection
Role: Director

Exact text from the filing

On March 28, 2025, Mr. John Schmid informed the Board of his decision to not stand for reelection as a director at the Company’s 2025 annual meeting of stockholders (the “2025 Annual Meeting”).

View on SEC.gov

Xeris Biopharma Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001867096-25-000054

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.